DYNOMICS
We target therapeutics to human heart function, taking a precision approach to drug development and capturing the adult heart clinical phenotype. This is powered by our scalable, authentic and predictive discovery engine - HeartDyno. HeartDyno is built with engineered human cardiac organoids, scalably deployed to drive a multi-omics data-driven approach. It rapidly uncovers novel therapeutic targets and candidates that offer superior efficacy and safety profiles in humans. Dynomics’ approach is validated through collaboration with top pharmaceutical companies, top-tier scientific publications, and we are progressing assets targeting heart failure, affecting 4% of the US population and where current treatments provide a 50% 5-year survival rate.
DYNOMICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2020-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.dynomics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
500 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Investors List
Boost VC
Boost VC investment in Pre Seed Round - Dynomics
Official Site Inspections
http://www.dynomics.com Semrush global rank: 5.98 M Semrush visits lastest month: 1.37 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Dynomics"
Dynomics - Crunchbase Company Profile & Funding
Dynomics’ approach is validated through collaboration with top pharmaceutical companies, top-tier scientific publications, and we are progressing assets targeting heart failure, affecting 4% …See details»
Dynomics - Human-predictive discovery to unlock precision …
HeartDyno, our human cardiac tissue discovery platform, to decode heart function. It identifies novel drug targets, new therapeutics, and target patient populations.See details»
Dynomics - LinkedIn
Dynomics | 421 followers on LinkedIn. Targeted therapies to eliminate heart failure. | Heart failure affects 4% of the US population, yet treatment options are primarily symptomatic, including ...See details»
Dynomics 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Dynomics. Use the PitchBook Platform to explore the full profile.See details»
Dynomics - Products, Competitors, Financials, Employees, …
About Dynomics Dynomics operates in the biotechnology sector, focusing on cardiac drug discovery. The company provides a discovery platform that uses a human cardiac tissue …See details»
Dynomics - Funding, Financials, Valuation & Investors
In funding over 1 round. This was a Pre-Seed round raised on Oct 17, 2020. Dynomics is funded by Boost VC.See details»
Dynomics Therapeutics - VentureRadar
"Dynomics develops molecules to restore heart function. We’ve developed HeartDyno, our cardiac organoid discovery engine, using scalable, authentic and predictive cardiac organoids …See details»
Dynomics - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 10, 2025 Dynomics - Provider of human cardiac organoids to develop targeted therapies for heart failure. Raised funding from 3 investors. Dynomics has 69 competitors.See details»
Dynomics - Updates, News, Events, Signals & Triggers
Molecules to restore heart function.See details»
Dynomics Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Dynomics Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Dynomics B.V. - VentureRadar
"Dynomics aims to be the worldwide leader in the development of tests that provide diagnostic information on the classification of leukemia and lymphoma and information on the prognosis …See details»
Drew Titmarsh - CEO and Co-founder at Dynomics | The Org
Drew Titmarsh has held a variety of roles in the field of bioengineering and regenerative medicine since 2005.See details»
Dynomics - Biotech Careers
Dynomics develops therapeutics to directly target the heart, using an authentic human cardiac organoid discovery engine. Business Areas: TherapeuticsSee details»
Publications - Dynomics
Development of a human cardiac organoid injury model reveals innate regenerative potential. Voges, H. K. et al. Development 144, 1118–1127 (2017). LinkSee details»
CEO & Co-founder - Dynomics - Dynomics | Forbes Technology …
Dynomics is targeting therapies to the heart and its function, to eliminate heart failure. Our discovery platform, HeartDyno™, identifies superior molecular targets and therapeutics that …See details»
Dynomics - Contacts, Employees, Board Members, Advisors
Dynomics has 1 current employee profile, CEO and Co-founder Drew Titmarsh.See details»
James Hudson - Co-Founder at Dynomics | The Org
In 2020, they became a Co-Founder of Dynomics. James Hudson obtained a Doctor of Philosophy (PhD) in Biotechnology from The University of Queensland between 2007 and 2010.See details»
Dynomics Biomedtech - Overview, News & Competitors
View Dynomics Biomedtech (www.dynomics.com) location in Madrid, Spain , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
Drew Titmarsh - CEO and Co-founder @ Dynomics - Crunchbase
Drew Titmarsh is the CEO and Co-founder at Dynomics. Additionally, Drew Titmarsh has had 1 past job as the CEO and Co-founder at Scaled Biolabs.See details»
Brendan Griffen - Chief Technology Officer & Co-Founder at …
Brendan Griffen has held a variety of positions in the technology sector over the past 16 years. In 2020, they became the Chief Technology Officer & Co-Founder of Dynomics. From 2016 …See details»